Related Experiment Video
Updated: Feb 23, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.3K
Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas
Lawrance K Chung1, Panayiotis E Pelargos1, Ann M Chan2
1Department of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Brain Tumor Pathology
|September 10, 2017
Summary
Epithelial membrane protein-2 (EMP2) is elevated in glioblastoma (GBM) and correlates with decreased survival. EMP2 may serve as a diagnostic and therapeutic target for gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Epithelial membrane protein-2 (EMP2) is implicated in various human cancers.
- Its role as a biomarker in glioma, particularly glioblastoma (GBM), requires further investigation.
Purpose of the Study:
- To evaluate Epithelial membrane protein-2 (EMP2) as a potential biomarker in gliomas.
- To correlate EMP2 expression levels with glioma grade and patient survival.
Main Methods:
- A tissue microarray of lower-grade gliomas (WHO grades II-III) and glioblastomas (GBM, WHO grade IV) was analyzed.
- EMP2 expression was quantified and dichotomized into low and high expression groups.
- Expression levels were correlated with clinical data, including patient survival and Ki-67 positivity.
Main Results:
- Mean EMP2 expression was significantly higher in GBMs (2.20) compared to lower-grade gliomas (1.68).
- A higher percentage of GBM samples exhibited high EMP2 expression (90.0%) versus lower-grade gliomas (52.6%).
- EMP2 expression ≥2 correlated with decreased patient survival (r = -0.39, P = 0.001) and increased Ki-67 positivity (r = 0.34, P = 0.008).
Conclusions:
- Elevated EMP2 expression is associated with glioblastoma (GBM).
- EMP2 expression levels correlate with glioma aggressiveness and patient survival.
- EMP2 shows potential as a molecular target for glioma diagnosis and treatment, possibly in conjunction with other biomarkers.
